Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates
The Oncologist · 07.09.2023 · 28 (9) · e843-e846
DOI: 10.1093/oncolo/oyad185 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, online erschienen am 19.06.2023. Verfasst von Michael Rainone und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Thrombocytopenia, Anemia, Immunoconjugates. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Trastuzumab emtansine and trastuzumab deruxtecan are widely used in breast cancer and other solid tumor malignancies. Thrombocytopenia is a common adverse event associated with the use of these agents that can lead to a treatment delay, reduction in dose intensity, and discontinuation. The role of thrombopoietin receptor agonists (TPO-RA) remains unknown in this setting. We report a case series of 6 individuals with breast cancer that experienced dose-reductions and therapy delays due to thrombocytopenia secondary to trastuzumab emtansine or trastuzumab deruxtecan therapy and received intervention with TPO-RA. All 6 were able to resume therapy with TPO-RA support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Department of Hematology and Hematopoietic Cell Transplantation, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
- Department of Medical Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
ORCID-Profile: Yuan Yuan, Vinod Pullarkat
Zitieren
APA
Rainone, M., Kasparian, S., Nguyen, T., Talwar, N., Yuan, Y., Mei, M., Mortimer, J. E., Waisman, J. R., Patel, N., & Pullarkat, V. (2023). Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates. The Oncologist, 28(9), e843-e846. https://doi.org/10.1093/oncolo/oyad185
Vancouver
Rainone M, Kasparian S, Nguyen T, Talwar N, Yuan Y, Mei M, et al. Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates. The Oncologist. 2023;28(9):e843-e846. doi:10.1093/oncolo/oyad185
BibTeX
@article{Rainone2023,
author = {Rainone, Michael and Kasparian, Saro and Nguyen, Tina and Talwar, Neel and Yuan, Yuan and Mei, Matthew and Mortimer, Joanne E and Waisman, James R and Patel, Niki and Pullarkat, Vinod},
title = {Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates},
journal = {The Oncologist},
year = {2023},
volume = {28},
number = {9},
pages = {e843--e846},
doi = {10.1093/oncolo/oyad185}
}
EUVIMED